This Week in Urology — Sep 25, 2026

This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.

Welcome to This Week in Urology. This week we're covering 10 notable papers spanning prostate cancer detection and risk stratification, endourology and stone treatment, and reconstructive and functional urology, with a biomarker story from advanced urothelial cancer along the way. Let's dive in.

We start with the problem of finding and grading prostate cancer more accurately. In Prostate Cancer and Prostatic Diseases, Rusu and colleagues report MUSegNet, a deep learning model trained to outline the prostate, the transition zone, and clinically significant cancer on micro-ultrasound [1]. The model was built from a modest set of 53 manually labelled micro-ultrasound exams, supplemented by unlabelled micro-ultrasound studies and a large archive of conventional b-mode scans, then tested in 73 independent patients across two institutions and compared head to head with six expert readers. Discrimination improved substantially over baseline models trained on manual labels alone, and sensitivity for significant cancer rose from roughly a quarter to about three quarters. It also edged out the human readers on both discrimination and sensitivity, and in cases where significant cancer was invisible on MRI, it flagged disease in about one in three. The catch is that performance was strongly location dependent, with posterior lesions detected far more reliably than anterior ones, and the authors are explicit that a larger cohort is needed before this informs biopsy targeting in practice. Alongside imaging, blood-based markers are being pushed toward the same question. Terracciano and colleagues, also in Prostate Cancer and Prostatic Diseases, prospectively studied 130 men undergoing robot-assisted radical prostatectomy and asked whether the Prostate Health Index and its density version predict what the pathologist finds [2]. Adverse pathology, meaning stage pT3 or higher or node-positive disease, was present in about two fifths of cases, and upgrading from biopsy to prostatectomy occurred in close to six in ten men. The Prostate Health Index was the strongest independent predictor of adverse pathological extension, with risk rising sharply above a value of 40, while the density version was the only marker independently associated with grade reclassification, particularly in men with PI-RADS 4 or 5 lesions. The authors frame these as complementary rather than competing markers. This is a single-centre study of modest size without external validation, so it is hypothesis-strengthening rather than practice-defining. And on how we actually obtain the tissue, a concise review in European Urology Focus by Kotecha and colleagues argues that in the screening and early detection setting, transperineal biopsy delivers better detection of clinically significant cancer and lower infection risk than the transrectal route, and that despite greater patient discomfort, the antibiotic-sparing profile supports its use in population-based screening programmes [3]. That is an expert synthesis rather than new trial data, but it aligns with the direction European guidance has been moving.

Staying with the prostate but moving to treatment, World Journal of Urology publishes a cautionary population-based analysis from Quarta and colleagues comparing cryotherapy with external beam radiotherapy in high-risk and very high-risk disease [4]. Using the Surveillance, Epidemiology, and End Results database across 2010 to 2022, they identified nearly 34,000 such patients, of whom fewer than one percent received cryotherapy despite no guideline endorsement for that indication. After propensity score matching and accounting for competing causes of death, ten-year cancer-specific mortality was about 17 percent after cryotherapy versus about 8 percent after radiotherapy, roughly a doubling of cancer-specific mortality risk, while death from other causes was essentially identical between groups. This is registry data with all the unmeasured confounding that implies, and the cryotherapy group numbered only 245 patients, but the direction is consistent with why guidelines have not endorsed the approach in high-risk disease.

Turning to advanced urothelial cancer, European Urology carries a real-world biomarker analysis from Cho and colleagues in 322 patients receiving first-line enfortumab vedotin plus pembrolizumab for metastatic disease [5]. Tumours with high NECTIN4 RNA expression, the target of the antibody-drug conjugate, showed longer overall survival, with a median of about 21 and a half months versus roughly 14 months, and an objective response rate of about 67 percent versus about 42 percent. High tumour mutational burden tracked similarly. Importantly, NECTIN4 expression remained an independent predictor of both survival and response on multivariable analysis, and it was not associated with outcomes in a separate cohort of 232 patients given pembrolizumab monotherapy, which argues the signal is genuinely about the drug conjugate rather than general prognosis. Patients whose tumours were low for both markers had the lowest likelihood of response. This is retrospective and there is no validated assay or threshold ready for clinic, but it is the most credible predictive signal yet in a regimen that has so far had none.

Endourology gives us this week's cleanest piece of trial evidence. In The Journal of Urology, Knoedler and colleagues report a multicentre randomised controlled trial across five United States centres comparing pulse-modulated Holmium YAG with the thulium fibre laser for dusting intrarenal stones between 5 and 20 millimetres [6]. One hundred and seventy-eight patients were randomised, and the primary outcome was a true zero-fragment stone-free rate on computed tomography at six to twelve weeks. The result was a dead heat: about 53 percent stone-free in each arm, with no significant difference in procedure time, laser time, laser efficiency, or complications. Retrospective and single-centre work had produced conflicting claims about thulium superiority; this trial does not support them within that stone-size range, and the authors conclude that surgeon and institutional preference can reasonably dictate the choice. Complementing that, World Journal of Urology publishes a European Association of Urology endourology group review by Shrestha and colleagues on high-frequency versus low-frequency laser lithotripsy, pooling 22 studies and just over 2,000 patients [7]. Stone-free rates and operative times overlapped substantially between frequency settings, and overall complication rates were low. The nuance worth carrying is that when high frequency was combined with high power, particularly with thulium fibre lasers for renal stones, ureteral injury rates of roughly 3 to 4 percent were reported, and infection rates rose with high-frequency, high-power holmium settings in larger stones. Bleeding patterns tracked with the laser technology rather than frequency. This is narrative synthesis of heterogeneous studies, not pooled trial data, so it defines a safety signal rather than a threshold.

Three papers round out reconstructive and functional urology. Lee and colleagues, in World Journal of Urology, report the multi-institutional CORRUS experience with robotic ureteral reconstruction for radiation-induced strictures, an anatomically hostile problem [8]. Across 42 consecutive patients treated between 2018 and 2024, most with distal strictures, surgeons used a mix of reimplantation, appendiceal and buccal graft ureteroplasty, and ileal ureter interposition, with indocyanine green fluorescence in more than half of cases. At a median follow-up of about 18 months, roughly 88 percent required no further intervention, with major complications in about 7 percent. It is retrospective and from high-volume reconstructive centres, so it describes what is achievable with expertise rather than what is generalisable. In Neurourology and Urodynamics, Vacca and colleagues pooled 24 studies and around 7,000 women to ask what prolapse surgery does to overactive bladder symptoms [9]. Overall, preexisting overactive bladder resolved in about three fifths of women, with no significant difference between vaginal, laparoscopic, robotic, or abdominal routes, and none between mesh-augmented and native tissue repairs. What did matter was the compartment: anterior or apical repair achieved resolution in about three quarters of women, compared with under a third after isolated posterior repair. De novo overactive bladder ranged from none up to about 14 percent, though only six studies reported it. Heterogeneity was high, but the compartment finding is useful for counselling expectations. Finally, Sevim and colleagues, again in World Journal of Urology, retrospectively analysed 425 men after a first episode of acute urinary retention from benign prostatic obstruction [10]. Prostate volume, retention volume, serum urea, and International Prostate Symptom Score were each independently associated with progression to early surgery, with symptom score showing the strongest discrimination. Intravesical prostatic protrusion added signal but with a wide, imprecise estimate. The model was internally validated only, and the authors explicitly flag that external validation is pending.

If you only have time for one paper this week, make it the multicentre randomised trial of Holmium YAG versus thulium fibre laser in The Journal of Urology [6]. It settles, with randomised evidence, a question that retrospective series had left genuinely contested, and it reframes laser choice as a matter of availability and familiarity rather than outcomes for stones up to two centimetres.

Here is what this week's evidence adds up to in urology. First, randomised data now show no outcome difference between the two dominant laser platforms for dusting intrarenal stones under two centimetres, while pooled observational data suggest the safety concern lies with high-frequency and high-power settings in combination rather than frequency alone. Second, prostate cancer detection is being pushed by both imaging artificial intelligence and blood-based markers, with micro-ultrasound deep learning outperforming expert readers in one small two-institution test set and the Prostate Health Index and its density version predicting adverse pathology and upgrading respectively, but both lines of evidence remain single or dual-centre and unvalidated externally. Third, registry data associate cryotherapy in high-risk disease with roughly double the cancer-specific mortality of external beam radiotherapy, consistent with the absence of guideline support, though confounding cannot be excluded. Fourth, NECTIN4 expression is the first credible predictive biomarker for enfortumab vedotin plus pembrolizumab, though it is retrospective and there is no clinic-ready assay. And fifth, in functional and reconstructive urology, the compartment repaired predicts overactive bladder resolution after prolapse surgery more than the surgical route does, and robotic reconstruction of irradiated ureters achieved durable success in around nine in ten patients at experienced centres.

That's your roundup for This Week in Urology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And think of one colleague — in any specialty — who never has time to keep up with the literature. Tell them about AudioScholar: a free ten-minute weekly for every specialty, to listen to in any podcast app, or to read at audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.